GLUCOPHAGE Drug Patent Profile
✉ Email this page to a colleague
When do Glucophage patents expire, and when can generic versions of Glucophage launch?
Glucophage is a drug marketed by Emd Serono Inc and is included in two NDAs.
The generic ingredient in GLUCOPHAGE is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glucophage
A generic version of GLUCOPHAGE was approved as metformin hydrochloride by ATLAS PHARMS LLC on January 24th, 2002.
Summary for GLUCOPHAGE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 164 |
Clinical Trials: | 346 |
Patent Applications: | 680 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GLUCOPHAGE |
Drug Sales Revenues: | Drug sales revenues for GLUCOPHAGE |
What excipients (inactive ingredients) are in GLUCOPHAGE? | GLUCOPHAGE excipients list |
DailyMed Link: | GLUCOPHAGE at DailyMed |
Recent Clinical Trials for GLUCOPHAGE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Arab Contractors Medical Centre | Phase 4 |
Peking University First Hospital | Phase 4 |
Turning Point Therapeutics, Inc. | Phase 1 |